公开(公告)号：US11878055B1

公开(公告)日：2024-01-23

申请号：US18341590

申请日：2023-06-26

Applicant: BioNTech SE

Inventor： Alexander Muik ,  Kena Anne Swanson ,  Qi Yang ,  Hui Cai ,  Ugur Sahin ,  Kayvon Modjarrad

IPC: A61K9/51 ,  A61K31/7105 ,  A61K31/7115 ,  A61K39/215 ,  A61P31/14 ,  C07K14/005 ,  A61K39/00

CPC classification number: A61K39/215 ,  C07K14/005 ,  A61K2039/53 ,  A61K2039/545 ,  A61K2039/55555 ,  A61K2039/70 ,  C12N2770/20022 ,  C12N2770/20034 ,  C12N2770/20071

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses.

公开(公告)号：US20230355732A1

公开(公告)日：2023-11-09

申请号：US18176283

申请日：2023-02-28

Applicant: BioNTech SE ,  Tron GGMBH

Inventor： Ugur Sahin ,  Claudia Paret ,  Kirsten Vormbrock ,  Christian Bender ,  Petra Simon ,  Christoph Hartmann ,  Stefanie Hubich ,  Thomas Bukur ,  Thorsten Litzenberger

IPC: A61K39/00 ,  C07K14/47 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: A61K39/0011 ,  C07K14/4748 ,  C12Q1/6886 ,  G01N33/57415 ,  A61K39/001189 ,  G01N33/57484 ,  A61K2039/507 ,  A61K2039/53 ,  A61K2039/70 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/16 ,  G01N2333/47

Abstract: The present invention relates to the treatment of cancer, in particular breast cancer, particularly triple-negative breast cancer. More particularly, the invention concerns methods and means for cancer treatment involving a specific set of tumor antigens.

公开(公告)号：US20230193296A1

公开(公告)日：2023-06-22

申请号：US18049593

申请日：2022-10-25

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Silke Holtkamp ,  Ozlem Tureci ,  Sebastian Kreiter

IPC: C12N15/68 ,  C12N15/67 ,  C12N15/85

CPC classification number: C12N15/68 ,  C12N15/67 ,  C12N15/85

Abstract: It was the object of the present invention to provide RNA with increased stability and translation efficiency and means for obtaining such RNA. It should be possible to obtain increased grades of expression by using said RNA in gene therapy approaches.

公开(公告)号：US20230075979A1

公开(公告)日：2023-03-09

申请号：US17698829

申请日：2022-03-18

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Alptekin Güler ,  Andreas Kuhn ,  Alexander Muik ,  Annette Vogel ,  Kerstin Walzer ,  Sonja Witzel ,  Stephanie Hein ,  Özlem Türeci

IPC: A61K39/215 ,  A61K31/7105 ,  A61K31/711 ,  A61K31/7115 ,  A61K31/712 ,  A61K9/51 ,  A61P31/14 ,  C12N15/11 ,  C12N15/67 ,  C12N15/88

Abstract: This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen.

公开(公告)号：US11559587B2

公开(公告)日：2023-01-24

申请号：US16578601

申请日：2019-09-23

Applicant: BioNTech SE ,  TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg—Universität Mainz gGmbH

Inventor： Ugur Sahin ,  Heinrich Haas ,  Sebastian Kreiter ,  Mustafa Diken ,  Daniel Fritz ,  Martin Meng ,  Lena Mareen Kranz ,  Kerstin Reuter

IPC: A61K48/00 ,  A61K39/00 ,  A61K9/127

Abstract: The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

公开(公告)号：US20220356223A1

公开(公告)日：2022-11-10

申请号：US17621396

申请日：2020-06-23

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Sina Fellermeier-Kopf ,  Alexander Muik ,  Mathias Vormehr ,  Lena Mareen Kranz

IPC: C07K14/55 ,  A61P35/00

Abstract: The invention relates to variants of interleukin-2 (IL2). In particular, the invention relates to a polypeptide comprising a mutein of human IL2 or of a functional variant of human IL2, wherein the human IL2 or functional variant thereof is substituted such that affinity for the βγ IL2 receptor complex (IL2Rβγ) is enhanced. In one embodiment, the human IL2 or functional variant thereof is further substituted such that affinity for the αβγ IL2 receptor complex (IL2αβγ) is reduced. In one embodiment, the polypeptide activates effector T cells over regulatory T cells. The invention also relates to polynucleotides coding for the polypeptides of the invention, host cells comprising the polynucleotides, pharmaceutical compositions comprising the polypeptides, polynucleotides or host cells, therapeutic or prophylactic methods of treatment using the polypeptides, polynucleotides, host cells or pharmaceutical compositions and medical preparations comprising the polypeptides, polynucleotides, host cells or pharmaceutical compositions.

公开(公告)号：US11298426B2

公开(公告)日：2022-04-12

申请号：US15895402

申请日：2018-02-13

Applicant: BioNTech SE

Inventor： Ozlem Tureci ,  Ugur Sahin ,  Sebastian Kreiter

IPC: A61K47/64 ,  A61K48/00 ,  C07K14/74 ,  C12N15/62 ,  C12N5/10 ,  C07K14/47 ,  C12N5/0783

Abstract: The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

公开(公告)号：US20210246191A1

公开(公告)日：2021-08-12

申请号：US16972794

申请日：2019-06-06

Applicant: BioNTech SE

Inventor： Ugur Sahin ,  Bonny Gaby Lui ,  Nadja Salomon ,  Joycelyn Wüstehube-Lausch ,  Matin Daneschdar ,  Hans-Ulrich Schmoldt ,  Markus Fiedler

IPC: C07K14/78 ,  C07K1/107 ,  G01N33/68 ,  G01N33/574

Abstract: The present invention relates to the diagnosis and treatment of diseases expressing Fibronectin Extra Domain B (EDB) such as diseases characterized by tissue remodeling and/or angiogenesis, in particular cancerous diseases, such as head and neck, brain, colorectal, lung, prostate and breast cancer. More particularly, the invention concerns peptides targeting Fibronectin Extra Domain B.

公开(公告)号：US11084882B2

公开(公告)日：2021-08-10

申请号：US16855703

申请日：2020-04-22

Applicant: GENMAB A/S ,  BioNTech SE

Inventor： Isil Altintas ,  David Satijn ,  Rik Rademaker ,  Paul Parren ,  Friederike Gieseke ,  Ugur Sahin

IPC: C07K16/28 ,  A61K39/395 ,  G01N33/569

Abstract: Multispecific antibodies binding to human CD40 and human CD137, methods for preparing such multispecific antibodies, and methods of using such multispecific antibodies for therapeutic or other purposes.

公开(公告)号：US12281322B2

公开(公告)日：2025-04-22

申请号：US17494601

申请日：2021-10-05

Applicant: BIONTECH SE ,  TRON-Translationale Onkologie an der Universitätsmedizin der Johanne Gutenberg-Universität Mainz gem

Inventor： Tim Beissert ,  Ugur Sahin ,  Mario Perkovic

IPC: C12N15/86

Abstract: The present invention embraces a RNA replicon that can be replicated by a replicase of alphavirus origin. The RNA replicon comprises sequence elements required for replication by the replicase, but these sequence elements do not encode any protein or fragment thereof, such as an alphavirus non-structural protein or fragment thereof. Thus, in the RNA replicon according to the invention, sequence elements required for replication by the replicase and protein-coding region(s) are uncoupled. According to the present invention the uncoupling is achieved by the removal of at least one initiation codon compared to a native alphavirus genomic RNA. In particular, the RNA replicon comprises a 5′ replication recognition sequence, wherein the 5′ replication recognition sequence is characterized in that it comprises the removal of at least one initiation codon compared to a native alphavirus 5′ replication recognition sequence. The replicase of alphavirus origin may be encoded by an open reading frame on the RNA replicon or on a separate RNA molecule. The present invention enables efficient and safe expression of a protein of interest in a cell or organism, but is not associated with undesired production of fragments of alphavirus non-structural protein. Methods of protein production in vitro and in vivo, as well as medical uses, are provided herein.